Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis
Naegelin, Y., Rasenack, M., Andelova, M., Von Felten, S., Fischer-Barnicol, B., Amann, M., Mehling, M., Kappos, L., Sprenger, T., Derfuss, T.Volume:
25
Language:
english
Journal:
Multiple Sclerosis and Related Disorders
DOI:
10.1016/j.msard.2018.07.005
Date:
October, 2018
File:
PDF, 1.63 MB
english, 2018